Vildagliptin (LAF237) is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4; EC 3.4.14.5, also known as CD26) for the treatment of type 2 diabetes mellitus1. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.